Novel modifications in the series of O-(2-phthalimidoethyl)-N-substituted thiocarbamates and their ring-opened congeners as non-nucleoside HIV-1 reverse transcriptase inhibitors

Add time:07/20/2019    Source:sciencedirect.com

The structure–activity relationships (SARs) of N-aryl-O-(2-phthalimidoethyl)thiocarbamates (C-TCs) and their imide ring-opened congeners (O-TCs) as non-nucleoside HIV-1 reverse transcriptase inhibitors were further investigated. The SAR strategy involved modifications of the N-phenyl ring followed by the hybridization of the most promising N-aryl and O-(2-phthalimidoethyl) substructures. The role of stereochemistry and tert-butyl substitution of the phthalimidoethyl moiety on activity was also investigated. Seventy-six analogues were prepared by parallel solution-phase synthesis. Twenty-two C-TCs displayed nanomolar activity against wild-type HIV-1 and a number of analogues were effective against the Y181C mutant. Compound 56 combined the highest activity so far identified against Y181C (EC50 = 1.3 μM) with good potency against the K103R mutant (EC50 = 4.8 μM). Docking simulations helped to rationalize the SARs.

We also recommend Trading Suppliers and Manufacturers of 2-[[1-(4-chlorophenyl)cyclohexyl]oxy]ethyl(diethyl)ammonium chloride (cas 13352-70-0). Pls Click Website Link as below: cas 13352-70-0 suppliers

Prev:Synthetic and structural chemistry of nickel(II)/1-METHYLBENZOTRIAZOLE (cas 13351-73-0) complexes
Next:Labelling studies of the ring opening of 1-bromo-2-chloro-3,3-dimethylcyclopropene)